Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$460K
Filings
70
Firms Hired
4
Active Period
2015–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
HALT Campus Sexual Violence Act
2026 · second_quarter · Firm: TODD STRATEGY GROUP
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5269
To amend the Family and Medical Leave Act of 1993 and title 5, United States Code, to clarify that organ donation surgery qualifies as a serious health condition.
2026 · third_quarter · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $30,000 · Firm income: —
Matched citations: HR4582
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $30,000 · Firm income: —
Matched citations: HR4583
District of Columbia Federal Immigration Compliance Act
2026 · third_quarter · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $30,000 · Firm income: —
Matched citations: S1522
HALT Campus Sexual Violence Act
2026 · second_quarter · Firm: TODD STRATEGY GROUP
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5269
To amend the Family and Medical Leave Act of 1993 and title 5, United States Code, to clarify that organ donation surgery qualifies as a serious health condition.
2026 · second_quarter · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $90,000 · Firm income: —
Matched citations: HR4582
Living Donor Protection Act of 2025
2026 · second_quarter · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $90,000 · Firm income: —
Matched citations: HR4583
District of Columbia Federal Immigration Compliance Act
2026 · second_quarter · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $90,000 · Firm income: —
Matched citations: S1522
To amend the Family and Medical Leave Act of 1993 and title 5, United States Code, to clarify that organ donation surgery qualifies as a serious health condition.
2026 · first_quarter · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $140,000 · Firm income: —
Matched citations: HR4582
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $140,000 · Firm income: —
Matched citations: HR4583
District of Columbia Federal Immigration Compliance Act
2026 · first_quarter · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Client expense: $140,000 · Firm income: —
Matched citations: S1522
HALT Campus Sexual Violence Act
2026 · first_quarter · Firm: TODD STRATEGY GROUP
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5269
HALT Campus Sexual Violence Act
2025 · fourth_quarter · Firm: TODD STRATEGY GROUP
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5269
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (HR5269) -Prior authorization of molecular tests
Client expense: $110,000 · Firm income: —
Matched citations: HR5269
HALT Campus Sexual Violence Act
2025 · third_quarter · Firm: TODD STRATEGY GROUP
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Client expense: — · Firm income: $60,000
Matched citations: H.R.5269
HALT Campus Sexual Violence Act
2025 · third_quarter · Firm: TODD STRATEGY GROUP
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Client expense: — · Firm income: —
Matched citations: H.R.5269
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (HR5269) -Prior authorization of molecular tests
Client expense: $90,000 · Firm income: —
Matched citations: HR5269
Transplant reimbursement. HR.4128 - VALID Act.
Client expense: — · Firm income: $40,000
Matched citations: HR.4128
Transplant reimbursement. HR.4128 - VALID Act.
Client expense: — · Firm income: $40,000
Matched citations: HR.4128
Transplant reimbursement. HR.4128 - VALID Act.
Client expense: — · Firm income: $40,000
Matched citations: HR.4128
Transplant reimbursement. H.R.4128 - VALID Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.4128
Transplant reimbursement. H.R.4128 - VALID Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.4128
Immunosuppressive drug coverage implementation. S.3404: VALID Act of 2020.
Client expense: — · Firm income: $40,000
Matched citations: S.3404
Immunosuppressive drug coverage implementation. S.3404: VALID Act of 2020.
Client expense: — · Firm income: $40,000
Matched citations: S.3404
Protecting Access to Medicare Act of 2014
2017 · fourth_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payments for clinical laboratory tests. Medicare treatment of outpatient reimbursements for laboratory tests.
Client expense: — · Firm income: —
Matched citations: H.R. 4302
Source: Senate LDA